Extended Data Fig. 3: Proportion of patients with IGA PN-S score 0 or 1. | Nature Medicine

Extended Data Fig. 3: Proportion of patients with IGA PN-S score 0 or 1.

From: Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

Extended Data Fig. 3: Proportion of patients with IGA PN-S score 0 or 1.

Patients with IGA PN-S score 0/1 over time, by visit, to week 24 in PRIME (a) and PRIME2 (b). *P < 0.05; **P < 0.01; ***P < 0.001. ‘Responder’ was defined as a patient with IGA PN-S score of 0 or 1. Cochran-Mantel Haenszel test was performed on the association between responder status and intervention group, adjusted by documented history of atopy (atopic/non-atopic), stable use of TCS/TCI (yes/no), region and baseline antidepressant use (yes/no). P values are non multiplicity-controlled.IGA PN-S, Investigator’s Global Assessment for PN-Stage; TCI, topical calcineurin inhibitors; TCS, topical corticosteroids.

Back to article page